TP53 and cancer: Cancer therapy (such as radiotherapy or chemotherapy with platinum agents) can select CH clones with mutations in DNA damage response genes (including TP53, PPM1D and CHEK2), where the treatment dose is positively correlated with the enrichment of these CH mutations.14